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Ninety-five percent of the population are estimated to carry at least one genetic variant
that is discordant with at least one medication. Pharmacogenomic (PGx) testing has
the potential to identify patients with genetic variants that puts them at risk of adverse
drug reactions and sub-optimal therapy. Predicting a patient’s response to medications
could support the safe management of medications and reduce hospitalization. These
benefits can only be realized if prescribing clinicians make the medication changes
prompted by PGx test results. This review examines the current evidence on the impact
PGx testing has on hospital admissions and whether it prompts medication changes. A
systematic search was performed in three databases (Medline, CINAHL and EMBASE) to
search all the relevant studies published up to the year 2020, comparing hospitalization
rates and medication changes amongst PGx tested patients with patients receiving
treatment-as-usual (TAU). Data extracted from full texts were narratively synthesized
using a process model developed from the included studies, to derive themes associated
to a suggested workflow for PGx-guided care and its expected benefit for medications
optimization and hospitalization. A meta-analysis was undertaken on all the studies that
report the number of PGx tested patients that had medication change(s) and the number
of PGx tested patients that were hospitalized, compared to participants that received
TAU. The search strategy identified 5 hospitalization themed studies and 5 medication
change themed studies for analysis. The meta-analysis showed that medication changes
occurred significantly more frequently in the PGx tested arm across 4 of 5 studies.
Meta-analysis showed that all-cause hospitalization occurred significantly less frequently
in the PGx tested arm than the TAU. The results show proof of concept for the use of
PGx in prescribing that produces patient benefit. However, the review also highlights the
opportunities and evidence gaps that are important when considering the introduction of
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PGx into health systems; namely patient involvement in PGx prescribing decisions, thus
a better understanding of the perspective of patients and prescribers. We highlight the
opportunities and evidence gaps that are important when considering the introduction
of PGx into health systems.
Keywords: pharmacogenetic testing, hospital admission, medication change, adverse drug reaction, patient care
pathway, medicines optimization
INTRODUCTION
Many individuals carry genetic variants that can have a
profound impact on how they respond to medications
(McInnes et al., 2021). Pharmacogenomics (PGx) is the use
of genomic information to understand individual responses
to medications. PGx promises a personalized approach to safe
and effective management of health conditions and reducing
the inappropriate use of multiple medications (inappropriate
polypharmacy), by guiding the selection of appropriate
medications (Sharp et al., 2019).
Genetic variants are described as being discordant with a
medication when the genetic variant predisposes an individual to
having an unfavorable response to medications. An unfavorable
drug response can consist of an adverse drug reaction or poor
drug efficacy (Wei et al., 2012). For example, patients with
a variation of the CYP2D6 gene that makes them ultra-rapid
metabolisers of the analgesic, codeine, may experience an adverse
event such as respiratory depression which can prove fatal
(Kirchheiner et al., 2007). An example of poor drug efficacy
relates to people with loss-of-function variants of the gene
CYP2C19 that make them poor metabolisers of clopidogrel
so they are unable to derive therapeutic benefit from taking
the medication (Brown and Pereira, 2018). The potential for
unfavorable response to medications in the general population
due to PGx variants is high, with 95% of the population estimated
to carry one or more genetic variants that are discordant with at
least one medication (Van Driest et al., 2014; Bush et al., 2016;
Ji et al., 2016; Mostafa et al., 2019). Participants of a large study
that analyzed PGx genetic variation in the UK Biobank, found
that participants on average had discordant genetic variants to at
least 10 medications (McInnes et al., 2021). A study in the USA
found that 50% of patients with Medicare health insurance aged
65 and over, received at least one medication affected by genetic
variability, sometimes referred to as a PGx medications, with 25–
30% receiving at least two PGxmedications (Mostafa et al., 2019).
Discordant variants are potentially actionable, i.e., amenable to
PGx-guided change in prescribing for an individual to optimize
medication effectiveness and to reduce adverse effects.
Older people are more likely to have multiple health
conditions (multimorbidity) and be prescribed multiple
medications (polypharmacy) (Pedrós et al., 2014). Polypharmacy
is associated with an increased risk of adverse drug reactions
(Hanlon et al., 2018) and hospitalization (Alexopoulou et al.,
2008; Leendertse et al., 2008; Pedrós et al., 2014). Pedrós et al.
(2014) reports a 5 and 9-fold increased risk in hospitalizations
related to adverse drug reactions amongst patients using more
than three and 10 medications, respectively. In addition, people
aged 65 and over constituted 76% of hospitalizations related to
adverse drug reactions in the study (Pedrós et al., 2014). Age
and polypharmacy are identified as independent risk factors
of hospitalizations related to adverse drug reactions (Pedrós
et al., 2014). Therefore, if 20–40% of variability to medication
response between individuals is due to a patient’s genetic
profile (Ingelman-Sundberg, 2001), then the development of
intervention strategies like PGx-guided therapy could aid the
tailoring of dose and dosing regimen, or selection of medications,
to a patient’s genetic profile. Tailoring medication using PGx
information, could reduce adverse drug reactions so that
hospitalization related to adverse drug reactions is reduced,
especially in older people who are more vulnerable to the
consequences of inappropriate prescribing.
As institutions and healthcare systems look to begin adopting
PGx-guided prescribing (Luzum et al., 2017; Alshabeeb et al.,
2019; Turner et al., 2020), it is important to understand its
potential for improving patient outcomes and its effect on
prescribing practice. At the time of this writing, we are not
aware of any review that considers the effectiveness of PGx
testing on medication changes and hospital admissions. To
construct a patient care pathway that incorporates PGx-guided
pharmacotherapy, it is important to know whether a planned
intervention results in changes to prescribing and improved
patient outcomes. If PGx testing can lower medication-related
hospital admissions, then PGx testing has the potential to
improve medications safety and efficacy in patients, as well
as potentially producing cost-savings for health care systems.
The aim of this rapid review, therefore, is to synthesize the
current evidence that associates PGx testing and unplanned
hospital admissions and whether prescribers accept PGx-guided
recommendations for changes to prescribed medication.
METHODS
This rapid review used systematic review methodology (Grant
and Booth, 2009) and adheres to the Preferred Reporting Items
for Systematic Review (PRISMA) with meta-analysis (Liberati
et al., 2009).
Criteria for Considering Studies
We used the PICOS (Population, Intervention, Comparator,
Outcome, Settings) tool to identify relevant keywords/Medical
Subject Headings (MeSH) words.
Type of Participants
Any participants taking medication for a health condition.
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Type of Intervention and Comparator
PGx testing as an intervention compared to standard
pharmacotherapy not guided by PGx.
Type of Outcomes
Frequency of hospitalization and medication changes made by
the prescriber.
Study Settings
Studies were included with PGx-guided pharmacotherapy
implemented in either primary or secondary care settings of a
healthcare system, irrespective of specialization (e.g., psychiatry,
cardiothoracic, general) or country.
Search Strategy
Boolean operators AND/OR were used to combine search terms
and the use of Medical Subject Headings (MeSH) helped to
retrieve information from the relevant topic area regardless of the
terms used by the authors to refer to the same concept or spelling.
Two literature searches were conducted discretely for the
themes “hospital admission” and “medication change.” The
literature search for the “hospital admission” theme was
conducted using MEDLINE (EBSCOHost platform), CINAHL
(EBSCOHost platform) and Embase. An information specialist
was consulted to ensure an adequate balance of sensitivity and
specificity in the search strategy used. We used the following
databases to identify primary research studies for inclusion.
• MEDLINE 2000 to 2020, EBSCOHost (searched 10th
January 2021).
• CINAHL 2016 to 2020, EBSCOHost (searched 10th
January 2021).
• Embase 1996 to 2021, searched (searched 10th January 2021).
Electronic Searches
Searches were conducted using the following sources below.
Hospital Admission Themed Searches
Medline and CINAHL (EBSCOHost platform)—the
keywords used were [(MH “Pharmacogenetics”) OR (MH
“Pharmacogenomic Testing”) OR (MH “Pharmacogenomic
Variants”)] AND [(MH “Patient Admission”) OR (MH “Patient
Readmission”) OR (MH “Hospitalization”)].
Embase- the keywords used were [(“pharmacogenetic
testing”/exp OR “pharmacogenetic analysis” OR
“pharmacogenetic screening” OR “pharmacogenetic study”
OR “pharmacogenetic testing” OR “pharmacogenomic analysis”
OR “pharmacogenomic screening” OR “pharmacogenomic
study” OR “pharmacogenomic testing” OR “genotyping”) AND
(“hospital admission” OR “readmission”)].
Medication Changes Themed Search
Medline (EBSCOHost platform)- the keywords used were
[“test∗” AND ((MH “Pharmacogenomic Testing”) OR
“pharmacogenomic” OR (MH “Pharmacogenetics”) OR
“pharmacogenetic∗” OR (MH “Pharmacogenomic Variants) OR
“variant∗” OR “genotype∗”))] AND (“medication change∗” OR
“medicine change∗” OR [(“change” AND (“medication” OR
“prescription” OR “drug”))].
We did not apply any limits on language or publication date.
We searched all databases from inception to the date of search
(10th January 2021).
The hospital admissions theme was the first literature search
that was undertaken, and it became apparent that all the records
selected for narrative synthesis could be found in the MEDLINE
database and the records on MEDLINE were more relevant to
the topic of study than the records from the other two databases
used. As a result of this observation and the timely manner
to which rapid reviews aim to achieve evidence synthesis, only
MEDLINE (EBSCOHost platform) was used to conduct the
literature search for the “medication change” theme. Clavirate
analytics EndNote web was the citation manager used to store
the search results which were de-duplicated both using EndNote
and completed manually1.
Study Selection
The eligibility criteria used for the selection of studies are based
on the PICOS (Population, Intervention, Comparison, Outcome
and Setting) framework. The included studies featured patients
taking medication (population), pharmacogenomic testing as an
intervention, compared to standard pharmacotherapy not guided
by pharmacogenomics, with hospitalization or medication
adjustments as an outcome. Experimental (i.e., RCTs) and
observational studies set in primary/secondary facets of the
healthcare system were included. This framework was used as
a screening-and-selection tool for a two-stage screening and
selection process. At the first stage, the title and abstract of
each article was screened independently by one reviewer (VD),
for relevancy to the area of pharmacogenomic testing, hospital
admission and medication changes. For the hospital admission
themed studies, a co-author (MR) double screened the title and
abstract for 10% of the total number of articles. In the second step,
the full texts for the selected studies were obtained and they were
assessed for inclusion using the PICOS framework by VD.
Quality Assessment Tool
The methodologically diverse nature of the research designs used
across the eligible studies required three CASP checklists for
the three eligible study designs (randomized control trial, case-
control study and cohort study) be used to critically appraise
the validity, trustworthiness and reliability of the studies. Three
checklists were used as quality assessment tools:
• The new CASP critical appraisal tool for randomized
controlled trials (RCTs) standard checklist that takes into
account the widely adopted CONSORT 2010 guideline for
reporting RCTs2.
• CASP critical appraisal tool for cohort study3.
• CASP critical appraisal tool for case control study4.
1Endnote online 2021. Clarivate.
2Critical Appraisal Skills Programme, CASP (Randomized Controlled Trial)
Checklist. 2020.
3Critical Appraisal Skills Programme, CASP (Cohort Study) Checklist. 2018.
4Critical Appraisal Skills Programme, CASP (Case Control Study) Checklist. 2018.
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Information about study design was collected to help select an
appropriate CASP (critical appraisal skills programme) appraisal
tool and to assess study quality for each study so that the strength
of the studies could be established. Information on age, specialty,
setting, test, and genes tested will help to determine potential
barriers and facilitators to implementing pharmacogenomic
testing in routine clinical practice. The CASP checklists used
in this rapid review, were modified to exclude non-relevant
questions that ask the reviewer to consider the applicability of
results to meet local needs.
Data Extraction
Data extraction was independently carried out from five “hospital
admission” themed studies and five “medication change” themed
studies. The following information for all the studies was
extracted: study characteristics (author, study design, number
of participants, mean age of participants, specialty, setting,
single-gene or panel test, pharmacokinetic/pharmacodynamic
genes tested, whether a pharmacist featured in reviewing
pharmacogenomic test results/recommendations, outcome
variable and outcomes).
Narrative Synthesis
A narrative synthesis of studies meeting the inclusion criteria,
was conducted. Narrative synthesis involves combining the
findings of multiple studies using a textual approach to create
a summary and explain the findings from the included studies
(Popay et al., 2006). The method of narrative synthesis is
used when substantial methodological and clinical heterogeneity
between studies render studies non-amenable to meta-analysis.
However, a forest plot is used, to present results in a
clear way.
The results section describes the inclusion/exclusion of
studies, presents the data extracted from studies from both
FIGURE 1 | PRISMA flow diagram of literature search and included studies on hospital admissions. Adapted from Liberati et al. (2009). *Excluded studies with
reasons can be found in Table 1.
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FIGURE 2 | PRISMA flow diagram of literature search and included studies on medication changes themed studies. Adapted from Liberati et al. (2009). *Excluded
studies with reasons can be found in Table 2.
themes (hospital admission and medication changes) and a
summary of the effectiveness results of PGx testing on hospital
admissions and medication changes.
The quantative data from all studies for all-cause
hospitalization was combined for meta-analysis, as presented in
a forest plot and associated table.
Data Analysis
A meta-analysis of the quantitative data on all-cause
hospitalization and occurrence of medication changes
was conducted for the hospitalization themed studies and
medication change themed studies. The meta-analysis was
performed using Review Manager 5.4.15 and is presented
in two separate forest plots for the hospitalization themed
studies and medication change theme studies. Both forest
5Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane
Collaboration 2020.
plots used a random effect model for meta-analysis to
account for heterogeneity between the included studies.
All outcomes were handled as dichotomous variables
and odds ratios with 95% confidence intervals (95% CI)
were calculated.
Heterogeneity was tested with Chi2 and I2 tests. Thresholds
for the interpretation of I2 values were interpreted as “might
not be important” (0–40%), “moderate” (30–60%), “substantial”
(50–90%), and “considerable” (75–100%) heterogeneity with a
p < 0.1 considered significant, as suggested by the Cochrane
Handbook (Deeks et al., 2021). Given the large heterogeneity
that was observed, we undertook a Baujat plot analysis (Baujat
et al., 2002) which is a diagnostic plot to detect studies which
are believed to be excessively contributing to the heterogeneity
of a meta-analysis. The plot shows the contribution to the
overall heterogeneity of each study as measured by Cochran’s
QQ (X-axis) vs. its influence on the pooled effect size on the Y-
axis. Influence analyses proposed by Viechtbauer and Cheung
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(2010) was also conducted to identify the influential studies
with extreme values in the graphs. Both the Baujat plot and
the Influence analyses were performed in R language using the
Harrer et al. (2021) handbook.
RESULTS
Inclusion and Exclusion of Studies
The search strategy identified a total of 3,221 studies for both
“hospital admissions” (n = 1,621) and “medication changes” (n
= 1,600) themes (Figures 1, 2). Duplicates were removed and
the remaining studies underwent a two-stage screening process
that excluded 3,186 (at title and abstract screening stage) and 15
studies at the full-text articles stage (see Tables 1, 2 for excluded
studies) in total from both themes. Five hospital admissions
and five medication change themed studies were identified that
met inclusion criteria that were amenable for data extraction
(Tables 3, 4).
Quality Assessment
The included studies were assessed for risk of bias
(methodological quality) using the CASP checklists for three
types of study designs: randomized controlled trials, case-control
study and cohort studies. The bias risk assessment results of
the studies show that the overall quality of the studies is good.
The main problems are the identification of all-important
confounders in the cohort studies and blinding in the RCTs as
shown in Supplementary Tables 1, 2. Confounding factors, such
as kidney and liver function, are not considered in the cohort
studies, although they are potential risk factors for adverse drug
reactions (Brixner et al., 2016). One RCT was a single-blinded
study, two open-label studies (Elliott et al., 2017; Perlis et al.,
2018), one triple blinded study (Hall-Flavin et al., 2013) and one
double-blinded study (Tuteja et al., 2020).
Summary of the Study Characteristics
The included studies were all published between 2010 and 2020,
all conducted in the USA. A summary of study characteristics
for medication change themed studies and hospital admission
themed studies are shown inTables 3, 4, respectively. Five studies
reported hospital admission, four studies reported medication
changes and one study (Brixner et al., 2016) reported both
hospital admissions and medication changes.
The reviewed studies included both observational and
experimental research methodologies: one case-control study
(Perlis et al., 2018), three cohort studies and five randomized
controlled studies.
TABLE 1 | Characteristics of excluded hospital admission theme studies.
Reference Reason for exclusion
Kim et al. (2012) PGx was not applied for the purpose of guiding
pharmacotherapy.
TABLE 2 | Characteristics of excluded medication changes themed studies.
References Reason for exclusion
Carere et al. (2017) Genetic testing to guide non-prescribed medications
(i.e., over-the-counter medication or medications
purchased online without a prescription) and PGx testing
for the purpose of self-medication.
Ellis et al. (2019) Non-human DNA samples tested.
Perlis et al. (2020) Hospital admission or medication change not measured.
Povsic et al. (2019) Modeling of impact on hospital admissions or medication
changes, rather than the actual impact.
Vassy et al. (2018) This is a study protocol
Arwood et al.
(2020)
No comparison group receiving non-PGx guided therapy
Chialda et al.
(2008)
No comparison group receiving non-PGx guided therapy
Collins et al. (2020) No comparison group receiving non-PGx guided therapy
Ielmini et al. (2018) No comparison group receiving non-PGx guided therapy
Lorizio et al. (2011) No comparison group receiving non-PGx guided therapy
Papastergiou et al.
(2017)
No comparison group receiving non-PGx guided therapy
Patel et al. (2020) No comparison group receiving non-PGx guided therapy
Ruddy et al. (2013) No comparison group receiving non-PGx guided therapy
Sharma et al.
(2017)
No comparison group receiving non-PGx guided therapy
The average age of the participants in all the studies ranged
from 40 to 75 years old (Tables 3, 4). The studies covered
psychiatry and cardiovascular related conditions for 55% (n =
5) and 33% (n = 3) of the studies, respectively, while 22%
(n = 2) of the studies were cross-speciality, consisting of a
combination of internal medicine, primary care or elderly care.
The type of testing most used were panel tests (77% of all
studies reviewed, 7/9 that test for multiple genes and their
variants rather than single-gene tests). Both pharmacokinetic
and pharmacodynamic genes were tested for 77% (n = 7) of
all studies reviewed. Of all the included studies, pharmacists
reviewed PGx test results in only two studies (Brixner et al.,
2016; Elliott et al., 2017) and consultation with a pharmacist
was reported as optional in one study (Perlis et al., 2018). PGx
testing in the included studies occurred as part of the study
design so that hospitalization and medication changes in the
PGx tested arm of the study can be compared to the TAU
arm. PGx testing in the included studies were reactive and
included in the study designs. For the medication change themed
studies, two types of reactive PGx testing were observed: 1)
PGx testing occurring post-diagnosis with an indicated treatment
2) PGx testing occurring in response to poor efficacy or poor
tolerability to medication(s). Three out of the five studies selected
a population with a specific diagnosis or undergoing a procedure
that required subsequent pharmacotherapy (Hall-Flavin et al.,
2013; Winner et al., 2013; Tuteja et al., 2020). The remaining
two studies, Brixner et al. (2016) and Thase et al. (2019), selected
patients with a history of poor drug response to psychotropic
medication and polypharmacy patients taking medication with
potential for significant drug-gene interactions, respectively.

















































































Polypharmacy patients currently or initiating on
treatment with medication that has significant
drug-gene interaction, were recruited to both
arms of the study and only PGx tested in the
PGx-tested arm.
Yes The study reports that there was an average of
two recommendations per patient and 46% of





















Patients with major depressive disorder in both
arms of the study were PGx tested, but only in
the PGx-tested arm were the prescribers for
each patient provided with the PGx test results
for clinical use.
No Medication changes occurred in 76.8% of
participants from the PGx tested group and
44.1% of participants from the unguided
group. 10 (55.6%) out of 18 unguided patients
with significant drug-gene interactions had
medication changes and 15 (93.8%) out of 16
PGx tested patients with the same interaction
category had medication changes.
The PGx tested group, experienced greater
percent improvement in depression scores
from baseline on all three depression
instruments (HAMD-17, P < 0.0001;
QIDS-C16, P < 0.0001; PHQ-9, P < 0.0001)
compared with the TAU group. Eight-week
response rates were higher in the PGx tested
group than in the TAU group on all three
measurements depression rating tools
(HAMD-17, P = 0.03; QIDS-C16, P = 0.005;




















Patients with major depressive disorder who
had an inadequate response to at least one
psychotropic medication were randomized to
the PGx-guided arm or TAU. Patients from both
arms were PGx tested but only prescribers for
patients in the PGx-tested arm were provided
with PGx test results for clinical use.
No Medication changes during the first 8 weeks of
treatment were significantly more common in
the tested arm (65.8%; 235/357) than in the
TAU arm (52.3%; 225/430) (P < 0.001).
Among patients who switched medications,
HDRS-17 scores decreased by 30.0% from
baseline to week 8 in the tested arm compared























CYP2C19 Patients undergoing a percutaneous coronary
intervention requiring antiplatelet therapy, were
randomized to a PGx-guided arm or TAU. Only
the patients in the PGx-tested arm were PGx
tested.
No Medication changes (switch from clopidogrel to
alternative antiplatelets prasugrel/ticagrelor)
occurred in 30% of participants within the
PGx-guided arm and 21% of participants in the






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Generalizable Steps in PGx Process
As described above the nine studies were diverse in nature.
Five studies dealt with hospital admission four studies dealt
with medication changes (Hall-Flavin et al., 2013; Winner et al.,
2013; Thase et al., 2019; Tuteja et al., 2020) and one study
dealt with both hospital admissions and medication changes
(Brixner et al., 2016).
To aid derivation of themes for analysis, first a process
diagram was produced; derived from the steps described in
each of the studies (Figure 3). This PGx general process
model outlines the steps required for a PGx intervention that
can prompt medication changes, patient benefit and reduce
hospital admission.
Analysis of Included Studies in Relation to
a PGx General Process Model
Patient Groups
Patients included in studies presented with a range of
health conditions, but the focus was largely on those who
require polypharmacy regimens and long-term medication such
as warfarin, clopidogrel, antidepressants and antipsychotics
(Epstein et al., 2010; Hall-Flavin et al., 2013; Winner et al.,
2013; Brixner et al., 2016; Elliott et al., 2017; Perlis et al., 2018;
Thase et al., 2019; Ruaño et al., 2020; Tuteja et al., 2020).
The most common speciality studied was psychiatry, accounting
for 55% (5/9) of the included studies. The remaining studies
covered cardiology, primary care, elderly care, anticoagulation,
and internal medicine.
The type of PGx associated medications reported as used by
participants in all studies suggests patients in all the studies have
chronic conditions that require the use of medication long-term.
Two of the hospitalization themed studies, Brixner et al. (2016)
and Elliott et al. (2017) specifically recruited polypharmacy
patients, defined in the study as patients taking ≥3 medications
or participants taking an average of 11 medications, respectively.
Perlis et al. (2018) and Ruaño et al. (2020) recruited patients that
require psychotropic medication for major depressive disorder
and mood/anxiety disorders, respectively. From the medication
change themed studies, Tuteja et al. (2020) focused on patients
that require antiplatelet therapy with clopidogrel or its alternative
ticagrelor/prasugrel, after undergoing percutaneous coronary
intervention (PCI) with stent implantation. Hall-Flavin et al.
(2013), Winner et al. (2013) and Thase et al. (2019) focused on
patients that require treatment with psychotropic medication for
major depressive disorder.
Involvement of the Patient and Consent
While the consent requirements for routine PGx have not yet
been established, the patients in all the studies provided informed
consent on entry to the included studies (Epstein et al., 2010;
Hall-Flavin et al., 2013; Winner et al., 2013; Brixner et al., 2016;
Elliott et al., 2017; Perlis et al., 2018; Thase et al., 2019; Ruaño
et al., 2020; Tuteja et al., 2020).
DNA Sampling and Genetic Analysis
In each study, patients provided a buccal swab. In some
cases, the swabs were sent to an external laboratory for DNA



















































































Polypharmacy patients currently or initiating on
treatment with medication that has significant
drug-gene interaction, were recruited to both
arms of the study and only PGx tested in the
PGx-tested arm.
Yes At 4 months post-enrollment. Hospitalization
rate: 9.8% of patients in the tested arm vs.
16.1% in the TAU arm. Relative risk = 0.61, p
= 0.027
ED visits were 4.4% of patients in the tested
arm vs. 15.4% in the untested arm. Relative





















Patients initiated with at least one medication
with potential for significant drug-gene
interaction were recruited to the study and
randomized to the PGx-tested arm or TAU arm.
Only patients in the PGx tested arm were PGx
tested.
Yes At 60 days post-discharge. The mean number
of re-hospitalizations per patient was 0.33
(tested) vs. 0.7 (TAU). Relative risk = 0.48, p =
0.007
ED visits were 0.39 (tested) vs. 0.66 (TAU).
Relative risk = 0.58, p = 0.045
Composite number of re-hospitalization and ED























Patients new to warfarin treatment were PGx
tested and compared to a TAU arm that were
not PGx tested.
No Overall hospitalization-Hazard ratio = 0.69, p =
0.001
Hospitalizations for bleeding of


























Patients with a mood or anxiety disorder were
PGx tested in the PGx-tested arm and
compared to patients with the same diagnosis









The mean number of inpatient hospitalizations
per patient is 0.07 (tested) vs. 0.17 (TAU).
57.9% difference. P < 0.0001
The mean number of inpatient hospitalizations
for non-mood disorders is 0.05 (in tested
patients) vs. 0.14 (in TAU patients). 65.5%
difference. P < 0.0001
The mean number of ED visits is 0.19 (in tested
patients) vs. 0.33 (in TAU patients). 40.4%

























Patients with major depressive disorder were
randomized to the PGx -guided arm where
patients received PGx tests or TAU where
patients did not receive PGx test.
No Readmission rate within 30 days
post-discharge is 10.1% (99/982) for tested
patients and 9% (43/477) for patients receiving
TAU.
PK, pharmacokinetics; PD, pharmacodynamics. Intervention arm is the group of participants that had PGx testing with the intention to receive PGx -guided drug therapy. TAU, treatment-as-usual arm. Number of participants are the
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FIGURE 3 | PGx General process model for pharmacogenomic testing as an intervention.
isolation and gene analysis, whereas in some studies, this was
conducted in-house.
There is not currently a single standardized test or panel
for PGx, so each of the studies reported on different genotypes
that were selected to be appropriate to their patient population.
In the included studies, both single gene and panel PGx tests
were employed. The genotypes tested, and where published, are
included in Tables 3, 4, with one study (Perlis et al., 2018),
reporting on 3 of the 10 genes included in their analysis panel.
Laboratory Reporting of Genotype and
Laboratory/Provider Recommendations
Currently, there is no standardization of how genotype is
reported and how that information is associated with a patient’s
record so this will vary according to clinical setting and health
economy. In the hospitalization themed studies, clinical decision
support tools were utilized to report genotype results and
provide prescribing recommendations in Brixner et al. (2016),
Elliott et al. (2017), Perlis et al. (2018), and Ruaño et al.
(2020). In Epstein et al. (2010), no details were provided on
how genotype results and prescribing recommendations were
provided to the clinicians involved in patient care. In the
medication change themed studies, Hall-Flavin et al. (2013),
Winner et al. (2013) and Thase et al. (2019) all used a
clinical decision support tool to report genotype results and
provide recommendations. Tuteja et al. (2020) did not report
the use of a support tool but prescribers were provided
with prescribing decision support, using a widely used PGx
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FIGURE 4 | Forest plot showing the effect of PGx testing on medication changes compared to treatment-as-usual (TAU). The number of “events” are the number of
participants that received a medication change out of the total number of participants. Brixner et al. (2016) did not report the number of participants that received
medication changes in both the PGx tested and the TAU arm, was not included in the analysis.
prescribing guideline known as CPIC (Clinical Pharmacogenetics
Implementation Consortium).
Prescribing Recommendations
PGx reports aim to provide information for clinical teams
and prescribers to support medicine optimization such as
medications switch, change of dose or deprescribing. These
reports require review by team members with appropriate
expertise to understand and implement the recommendations
whilst exercising clinical judgement. In all the studies, prescribing
based on PGx guidance was at the discretion of the prescriber
(Epstein et al., 2010; Hall-Flavin et al., 2013; Winner et al., 2013;
Brixner et al., 2016; Elliott et al., 2017; Perlis et al., 2018; Thase
et al., 2019; Ruaño et al., 2020; Tuteja et al., 2020). Not all
the studies described the process by which PGx reports were
reviewed once received in the clinic (Epstein et al., 2010; Hall-
Flavin et al., 2013; Winner et al., 2013; Thase et al., 2019; Ruaño
et al., 2020; Tuteja et al., 2020). In some studies, a pharmacist
reviewed the report (Brixner et al., 2016; Elliott et al., 2017) or
was available for consultation (Perlis et al., 2018). None of the
studies reported patient’s involvement in decision-making.
The medication change themed studies suggest that
medication changes occurred as a result of the provision
of PGx information (Hall-Flavin et al., 2013; Winner et al.,
2013; Brixner et al., 2016; Thase et al., 2019; Tuteja et al.,
2020). However, only one of the published studies provide
detail on the proportion of PGx recommendations that were
implemented: Brixner et al. (2016) reported that 46% of 381
test recommendations were followed but did not report on the
number of patients that had medication changes.
Medication Changes
Four of the five medication themed studies provided data on the
number of patients with changes to medications that occurred
in the PGx-guided arm during the study period, compared to
the TAU arm. We note, as above, that these studies were varied
in relation to their settings, the number of genes tested, and
the number of medications that were likely to be able to be
changed as a result of PGx guidance. The analysis included all
measures of the number of patients that received medication
changes as derived from the publications, with per protocol
analysis undertaken for Hall-Flavin et al. (2013) and Thase et al.
(2019) so to exclude from the analysis participants whowithdrew.
In the PGx tested groups, 54.7% of patients had a medication
change, compared to 41.5% of changes in the TAU group,
representing a 32% increase in medication changes overall. The
quantitative data were combined for meta-analysis (Figure 4)
showing a statistically significant increase inmedications changes
in the PGx arm across 749 patients in the PGx-tested arm
and 825 patients in the TAU arm, with an odds ratio of 1.91
(Z = 2.67, p = 0.008). However, given the small number of
studies included and the diversity of settings, the heterogeneity
as measured by I2 was high (73%). The influence analysis
using the Baujat plot (Supplementary Figure 1A) highlighted
that the Hall-Flavin et al. (2013) study contributed much to
the overall heterogeneity whilst at the same time was not very
influential on the overall combined effect. Furthermore, in
Supplementary Figure 1Bwe show the Viechtbauer and Cheung
influence analyses (Viechtbauer and Cheung, 2010) which again
shows that Hall-Flavin et al. (2013) has a large influence on
heterogeneity as it is has very extreme values in these plots as
highlighted by the red spot.
Hospital Admissions
Five studies measured hospital admission, from a variety of
causes, as an endpoint of PGx-guided intervention. We note, as
above, that these studies were varied in relation to their settings,
the number of genes tested, and the medications changed as a
result of PGx guidance.
The quantitative data from each individual study for all-cause
hospitalization were available for meta-analysis, as presented
in a forest plot and associated table (Figure 5). The results of
the hospital admission themed analysis show that a reduction
in unplanned hospital admission occurred in four out of the
five studies. These data show that all-cause hospital admissions
occurred significantly less frequently in the PGx tested arm
incorporating data from 2,957 patients in the PGx-tested arm and
6,783 patients in the treatment as usual arm being significant,
with an odds ratio of 0.5 (Z = 3.01 p = 0.003). In the PGx
tested groups, 11.5% of patients had a hospital admission,
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FIGURE 5 | Forest plot showing the effect of PGx testing on hospitalization compared to treatment-as-usual. 95% CI, 95% confidence interval. The number of
“events” are the number of participants who were hospitalized during the reporting period of the study.
compared to 20.1% of changes in the TAU group, representing
a 43% reduction in hospital admissions for people receiving
PGx testing in these trials. However, given the small number of
studies included and the diversity of settings, the heterogeneity
as measured by I2 was high (87%). The influence analysis using
the Baujat plot (Supplementary Figure 2A) highlighted that the
Ruaño et al. (2020) study contributed much to the overall
heterogeneity and was very influential on the overall combined
effect. Furthermore, in Supplementary Figure 2B we show the
Viechtbauer and Cheung influence analyses (Viechtbauer and
Cheung, 2010) which again show that Ruaño et al. (2020) has a
large influence on heterogeneity as it has extreme values in these
plots (highlighted by the red spot).
Further details of the effect of PGx testing on all-cause
hospitalization measured in the studies are presented in Table 5
together with data on unplanned hospitalization and outpatient
visits where that was measured and reported in the studies.
For the three studies which reported unplanned hospital
admissions, there were consistent reductions in unplanned
hospitalization. Two studies measured outpatient visits (Brixner
et al., 2016; Perlis et al., 2018), with one study reporting a large
increase in outpatient visits among people receiving a PGx test
(Brixner et al., 2016) and one study reporting a slight decrease
(Perlis et al., 2018).
DISCUSSION
This study shows that currently, there are a limited number
of studies that compared PGx-guided pharmacotherapy with
treatment as usual in relation to the measurable patient outcomes
of medication changes and hospitalization. The published
evidence demonstrates the potential of PGx testing in a range
of settings to produce patient benefit. This is demonstrated
both from the narrative synthesis and also the meta-analysis
achieved through combining the results of all studies with
similar outcome measures. The analysis shows that PGx testing
can produce substantial benefits in patient populations, by
substantially increasing the number of medication changes that
could potentially result in a reduction in serious adverse events
as measured by hospital admission. Hospital admissions were
halved across the interventions included in this study. These
findings contribute to evidence for the clinical utility of PGx
testing which is often lacking in literature and altogether provide
strong proof-of-concept for the clinical utility of PGx testing in
guiding medication changes that result in clinical improvements
and that PGx testing can potentially reduce hospitalization.
Medication changes occuring as a result of undesirable drug
response, are to be expected in both PGx tested and TAU arms of
the study, and we showed (Figure 4) that PGx resulted in more
medication changes. In this study we have treated medication
changes as a desirable outcome indicating that prescribers have
acted on PGx information to review medications already in use
by patients to avoid undesirable or suboptimal drug resposnes.
In the studies analyzed, PGx tests were conducted on patients
who were already taking medications to treat diagnosed disease.
Therefore, in the studies reviewed here, PGx information should
prompt medication optimisation and change. This is borne out
in studies which reported on this: where PGx testing was done
it revealed numerous patients taking medcations with predicted
significant gene-drug interactions who were at risk of poor
drug response (Hall-Flavin et al., 2013; Winner et al., 2013;
Thase et al., 2019). Therefore, a switch or dose adjustment
in these cases is a positive outcome. It is important to note,
however once PGx testing becomes a routine part of prospective
prescribing decision making, it would be expected that fewer
medication changes would occur in patients receiving PGx-
guided treatment, as patients should be more likely to receive
medications and doses of those medications that are effective
and have fewer side effects than current treatment as usual.
A pre-emptive approach did not take place in these studies
but is being developed for storage of PGx information and its
future use (Relling and Evans, 2015; Lazaridis, 2019). Current
implementation studies with this intention are underway, for
example a 5-year prospective study started in 2016 known as
PREPARE (PREmptive Pharmacogenomic testing for preventing
Adverse drug REactions [ADRs]), conducted by the Ubiquitous
Pharmacogenomics (U-PGx) consortium (Manson et al., 2017).
The study aims to generate evidence, using multi-center RCTs,
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TABLE 5 | Risk of hospitalization in PGx-tested arm and control (treatment-as-usual) arm.
Author (Year), Country All-cause hospitalization (%) Emergency department visit (%) Outpatient visit (%)
Brixner et al. (2016), US Risk was reduced by 39% relative to the
control group. (RR = 0.61)
Risk was reduced by 71% relative to the
control group. (RR = 0.29)
Outpatient visits increased by 97% relative
to the control group. (RR = 1.97)
Elliott et al. (2017), US Risk was reduced by 52% relative to the
control group. (RR = 0.48)
Risk was reduced by 42% relative to the
control group. (RR = 0.58)
Not measured
Epstein et al. (2010), US 31% less likely to be hospitalized than patients
in the control group. (HR = 0.69)
Not measured Not measured
Perlis et al. (2018), US 58% difference between the intervention and
control group. (RR = 0.42)
40% difference between the intervention and
control group.
13% difference between the intervention
and control group.
Ruaño et al. (2020), US No significant difference between the
intervention and control group.
Not measured Not measured
The study outcomes are presented as relative risk, hazard ratio and percentage difference between the intervention and control group. Reduction in hospital admission is denoted by
the green downwards pointing arrow ( ), increase in outpatient visits denoted by the red upward pointing arrow ( ) and no signicant difference is denoted by the blue double
bidirectional arrow ( ).
for the effect of pre-emptive PGx testing on reducing ADRs by
considering multiple drugs, genes, ethnicities and health care
systems across seven European countries (Manson et al., 2017).
We note that it would be premature to draw a definitive
conclusion on the impact of PGx testing on medication changes
and hospital admissions, due to the nature of the studies that
are currently available. There are only a small number of
published studies which have included medication changes and
hospital admission end points. Whilst the published studies all
are well-designed and have reported appropriatetly, the studies
all have different designs. This leaves some significant gaps in
our understanding of how to ensure effectiveness of a PGx
intervention. Aspects that require consideration are mapped in
the generalized process model (Figure 3), namely the patients
who would most benefit from PGx testing, the genetic variants to
be routinely included in tests, how the information is provided to
clinical teams, and whether the recommendations are taken up.
One key question is whether interventions can be used with
larger populations with a wider range of conditions, for example
older patients on multiple medications. Improvement in clinical
outcome consists of symptom improvement and higher response
and remission rates. The extent of improvement possible from
PGx testing is dependent on the existing medications a patient
is on, their own genotype and the number of significant PGx
variants they have which predict a sub-optimal or harmful
response to a medication. Therefore, the choice of patients
for PGx-guided intervention is important. The majority of the
included studies focussed on a specific condition or group of
patients, and chose a small number of genes to test. We note
that clinical outcome improvements were observed particularly
in those who were taking medications with significant drug-
gene-interactions at baseline and then switched to medications
with no drug-gene interactions. Thase et al. (2019) found
that 66.4% of PGx-tested patients switched from medications
with significant drug-gene interactions to medications with
no drug-gene interactions and saw a 7.6% improvement in
depressive symptoms (HDRS-17 scores) at 8 weeks from baseline.
Patients taking medications with significant or modest drug-gene
interactions at baseline, reported greater clinical improvement
in the PGx-tested arm than TAU arm in Winner et al. (2013)
and Hall-Flavin et al. (2013). Thus, studies which are less
specifically targeted to patients who are taking medications
with significant drug-gene interactions may well have a smaller
impact on medication change compared to the studies that
were included and analyzed here. However, it is reassuring
that the studies of Brixner et al. (2016) and Elliott et al.
(2017) which studied older patient populations in non-specialist
settings both provided positive evidence that PGx testing reduces
hospitalization. Furthermore, a reduction in hospitalization
amongst PGx tested patients, infers the acceptance of PGx-
guided recommendations by prescribers. Hall-Flavin et al.
(2013) reported that PGx tested patients identified to be taking
medications categorized with significant drug-gene interactions,
were more likely to experience changes to their medications
than non-PGx tested patients taking medications in the same
category. PGx testing can help healthcare professionals predict
serious drug therapy problems for individual patients and
thus prescribers are more likely to accept subsequent PGx-
guided recommendations.
The majority of the included studies, except for Ruaño
et al. (2020) and Tuteja et al. (2020), recruited outpatients and
inform a care pathway with patients receiving PGx testing in a
primary care setting. We note that medication changes and new
medication initiations often occur in hospital, but PGx testing
for inpatients in secondary care is not yet well-represented in the
literature. Therefore, more studies are required to investigate how
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PGx testing could be used for hospital inpatients and how a care
pathway that incorporates PGx testing would work in practice in
these settings.
Improved medications optimisation and reduction in adverse
effects, particularly hospitalizations as well as benefiting patients,
offer potential cost-savings for health systems which are beyond
the scope of this review. However, we note that one study
reported a 39 and 71% reduction in the risk of inpatient
hospitalization and emergency department visit, respectively, but
a 97% increase in outpatient visits (Brixner et al., 2016), most
likely due to multiple appointments required to make changes to
the patient’s medications. Thus, the impact on other parts of the
health systems should be a consideration for cost-effectiveness
studies and the deisgn of a care pathway that considers both
the current workload of healthcare professionals and patient
convenience and benefit.
Genotyping was the genomic testing technology applied in the
included studies and the technology focuses on predetermined
genetic variants. This technology utilizes biochemical assays and
is usually cheaper than next generation sequencing in sequencing
variants in the tens to low hundreds (Mitropoulou et al., 2020).
For PGx-guided pharmacotherapy to benefit patients, PGx tests
should be predictive for the clinically important drug-gene
interactions relevant to the patient and should contribute to
improved health outcomes. For that reason, the PGx tests selected
should cover all genetic variants with significant evidence. In
these proof of concept studies, this was not always the case:
for example Ruaño et al. (2020) in their study focused on
psychiatry patients and tested a single gene, CYP2D6 whilst there
are currently other genes, including CYP2C19 with significant
evidence for variants that affect response to medications in
psychiatry (Hall-Flavin et al., 2013; Perlis et al., 2018; Thase et al.,
2019). Testing for just one gene in Ruaño et al. (2020) could
therefore underestimate the effect that PGx testing could have
on reducing hospitalization in patient populations. This seems
likely, since testing for genes CYP2C19 and CYP2D6 amongst
other genes, Perlis et al. (2018) reports a greater reduction
in hospitalization. Epstein et al. (2010) tested for common
genes associated with warfarin response, namely CYP2C9 and
VKORC1, before the gene CYP4F2 was recently added to
CPIC guidelines and inclusion of that gene may have further
improved the decrease in hospitalization observed. Conversely,
in some of the studies, gene variants have been included
which do not yet have consensus guidance on medications
used in the condition, so their predicted effect on patient
outcomes is not clear. For example the non- CYP2D6 and
non-CYP2C19 genetic variants tested in Hall-Flavin et al.
(2013), Winner et al. (2013), Perlis et al. (2018), and Thase
et al. (2019) are not known to have an important role in
psychiatry. In the future, a PGx test that includes the most
clinically relevant drug-gene interactions and preferably the
widest range of commonly prescribed medications, could be
most useful for routine care of general patient populations. PGx
panel testing for multiple medications is particularly important
when considering older patients, who are more at risk of
adverse drug reactions and are more likely to be prescribed
multiple medications. PGx testing is particularly attractive when
considering the risks associated with polypharmacy. A reactive
testing approach conducted on sub-populations at most risk
of adverse drug reactions, such as older people, will allow for
a more targeted approach in the use of healthcare systems’
finite resources.
The way in which laboratory tests are incorporated into
clinical decision support tools is an essential area for research
and development to ensure that the potential benefits of PGx
are maximized. In this analysis, six of the included studies used
proprietary software or algorithms to produce reports, and we
have not found published evidence of how the predictions are
constructed, their effectiveness and precision or their usefulness
to prescribers and healthcare staff. Decision support tools
with algorithms that take account of clinical parameters that
affect response to medications (i.e., age, body-mass-index ratio,
sex, renal, liver function, current medication in use) will be
appropriate in delivering personalized care for patients (Turner
et al., 2020). Since routine PGx-guided care is at an early
stage of development, the information needs of prescribers and
healthcare staff as well as their perception of PGx-guided care,
need to be considered. A Greek study reported that 50% of
pharmacists and medical doctors felt that they were unable to
provide sufficient information to patients explaining PGx test
results (Mai et al., 2014). Taking account of information needs
and perception amongst this group will ensure that decision
support tools can better support workflow for PGx prescribing.
Finally, we note that included studies provided little detail on
whether the recommendations in the PGx report were actioned,
with the exception of Brixner et al. who recorded that 46%
of test recommendations were followed. This detail is essential
for future PGx studies, to understand whether the medication
changes were genuniely PGx-guided or changed for other reasons
such as inclusion in a trial that might trigger a more complete
patient medications review than “treatment as usual.” Detail
of medication changes is lacking in the included studies and
exploration of whether prescribers felt more comfortable in
changing dose than changing medication or changing particular
types of medication is also absent. This knowledge is essential to
inform training for prescribers and to effectively deliver PGx-
guide care. When designing implementation strategies of PGx
acrosss health systems, such as the NHS, understanding how the
information is constucted so that it can be understood and acted
on by health professionals to implement PGx-guided medication
adjustments is critical. In addition, the patient’s involvement
in prescribing decisions is important; patient’s perspectives on
care affects adherence to pharmacotherapy and how they take
their medications (Joosten et al., 2008; Silva, 2012). Therefore,
investigating patient’s attitude to PGx testing can contribute
postively in making PGx-guided care more patient-centered.
CONCLUSION
Results from this study provide evidence that PGx testing
increases medication changes and reduces hospitalization and
also provide a proof-of-concept for the clinical utility of PGx-
guided care that informs future pharmacotherapy. The small
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number of studies reviewed demonstrates the novelty of the
review question, and our analysis contributes to identifying gaps
where further research is required, including study into the
perspectives of patients and prescribers to aid the design of
PGx-guided care that is patient-centered.
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